• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Dynavax Technologies Corporation - Product Pipeline Review - H2 2011 Product Image

Dynavax Technologies Corporation - Product Pipeline Review - H2 2011

  • ID: 1964329
  • November 2011
  • 117 pages
  • Global Markets Direct

Dynavax Technologies Corporation – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Dynavax Technologies Corporation - Product Pipeline Review - H2 2011” provides data on the Dynavax Technologies Corporation’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Dynavax Technologies Corporation’s corporate website, SEC filings, investor presentations and featured press releases, both from Dynavax Technologies Corporation and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Dynavax Technologies Corporation - Brief Dynavax Technologies Corporation overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Dynavax Technologies Corporation human therapeutic division.
- Overview of pipeline therapeutics READ MORE >

Note: Product cover images may vary from those shown



List of Tables
List of Figures
Dynavax Technologies Corporation Snapshot
Dynavax Technologies Corporation Overview
Key Information
Key Facts
Dynavax Technologies Corporation – Research and Development Overview
Key Therapeutic Areas
Dynavax Technologies Corporation – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Dynavax Technologies Corporation – Pipeline Products Glance
Dynavax Technologies Corporation Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Dynavax Technologies Corporation–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Dynavax Technologies Corporation – Drug Profiles
DV-601
Product Description
Mechanism of Action
R&D Progress
DV1079
Product Description
Mechanism of Action
R&D Progress
IRS 954
Product Description
Mechanism of Action
R&D Progress
N8295
Product Description
Mechanism of Action
R&D Progress
SD-101
Product Description
Mechanism of Action
R&D Progress
SD-101 + Ribavirin
Product Description
Mechanism of Action
R&D Progress
Dynavax Technologies Corporation – Pipeline Analysis
Dynavax Technologies Corporation – Pipeline Products by Therapeutic Class
Dynavax Technologies Corporation - Pipeline Products By Target
Dynavax Technologies Corporation – Pipeline Products by Route of Administration
Dynavax Technologies Corporation – Pipeline Products by Molecule Type
Dynavax Technologies Corporation – Recent Pipeline Updates
Dynavax Technologies Corporation – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Apr 30, 2009: Dynavax Presents Data From Novel Universal Flu Vaccine Candidate
Sep 29, 2009: Dynavax Initiates Phase III Registration Trial In Chronic Kidney Disease Patients For HEPLISAV Hepatitis B Vaccine
Nov 28, 2006: Dynavax's HEPLISAV Hepatitis B Vaccine Shows Statistically Significant Results In Phase III Trial
Sep 28, 2010: Dynavax Announces DSMB Clearance To Continue Two Phase III HEPLISAV Trials In CKD Patients
Jul 28, 2011: FDA Agrees With Dynavax On Consistency Of HEPLISAV Lots
Nov 27, 2007: Dynavax Reports Progress In Lupus Program With Inhibitor Of TLR7 And TLR9
Oct 27, 2011: Dynavax Confirms HEPLISAV Submission Strategies With FDA And EMA
Oct 27, 2011: Dynavax Phase III Data In Chronic Kidney Disease Demonstrates Superiority Of HEPLISAV Versus Engerix-B
Sep 27, 2005: Dynavax Introduces TOLAMBA And HEPLISAV Brand Name For Ragweed Allergy And Hepatitis B Vaccine Product
Sep 27, 2005: Dynavax Introduces TOLAMBA Brand Names for Ragweed Allergy
Jul 27, 2010: Dynavax Completes Enrollment And First Immunizations In Universal Flu Vaccine Study
May 27, 2010: Dynavax's Two Phase III HEPLISAV Trials Cleared By DSMB To Continue Immunizations
Apr 27, 2010: Dynavax's Two Phase III HEPLISAV Trials Cleared By DSMB To Continue Immunizations
Apr 27, 2009: Dynavax Presents Additional Phase III Data For HEPLISAV Hepatitis B Vaccine At EASL Medical Conference
Jun 26, 2007: Dynavax Starts HEPLISAV Phase III In Europe; U.S. Study; And Phase II In ESRD In Canada
Apr 26, 2010: Dynavax Reports Positive Data On Universal Flu Vaccine Candidate
Jan 26, 2010: Dynavax Reports Positive Phase 1b Data for SD-101 in Chronic Hepatitis C Infection
Oct 25, 2011: Data From Two Phase III Studies Demonstrate HEPLISAV's Superiority In Immunizing Persons With Diabetes From Hepatitis B
May 25, 2011: Dynavax Completes Phase III Study Of HEPLISAV
Feb 25, 2010: Dynavax Selects Clinical Vaccine Candidate For Universal Flu Program
Mar 24, 2010: Dynavax Reports Positive Findings From Detailed Safety Analysis Of HEPLISAV
Dec 23, 2010: Dynavax Reports Phase IB Safety And Immunogenicity Results For Hepatitis B Therapy Candidate
Sep 23, 2010: Dynavax Initiates Phase Ib Study For Universal Flu Vaccine
Jun 23, 2005: Dynavax Initiates Pivotal Phase III Trial For Hepatitis B Vaccine
Feb 23, 2011: Dynavax's Two Phase III HEPLISAV Trials Cleared By DSMB To Continue To Study Completion
Sep 22, 2008: Dynavax Receives Milestone From AstraZeneca
Jun 22, 2004: Dynavax Announces Initiation Of Phase II/III Hepatitis B Trial
Feb 22, 2011: Dynavax Reports Additional Positive Phase IB Immunogenicity Data For Hepatitis B Therapy Candidate
Feb 22, 2011: Dynavax Reports New Phase Ia And Phase Ib Data For Universal Flu Vaccine Candidate
Oct 21, 2008: Dynavax And Merck & Co., Inc. Provide Update On U.S. FDA Clinical Hold On Investigational Vaccine HEPLISAV
Dec 20, 2006: Dynavax Initiates Pivotal Phase III Trial For HEPLISAV, Hepatitis B Vaccine
Oct 20, 2004: Dynavax To Present Data On Phase II Clinical Trial Of Hepatitis B Vaccine At ICAAC
Jul 20, 2011: Dynavax Phase III Demonstrates Superiority And Safety Of HEPLISAV Compared With Engerix-B
Apr 20, 2011: Dynavax Initiates First Human Trial In Lupus Program
Dec 19, 2005: Dynavax's HEPLISAV Hepatitis B Vaccine Shows Statistically Significant Efficacy In Phase 2/3 Clinical Trial
Nov 19, 2009: Dynavax Completes Enrollment Of First Cohort Of Patients In Phase Ib Clinical Trial For Hepatitis B Therapy
Sep 19, 2007: Dynavax's HEPLISAV Hepatitis B Vaccine Maintains Full Immunogenicity At 50 Weeks In Phase III Trial
Sep 18, 2011: Dynavax Reports Complete Results From HEPLISAV Phase III Trial In Healthy Adults Over Age 40
Feb 18, 2010: GlaxoSmithKline Picks One Drug Molecule From Dynavax Deal
Mar 17, 2010: Dynavax Anticipates Earlier BLA Submission For HEPLISAV
Mar 17, 2008: Dynavax And Merck & Co., Inc. Report Clinical Hold Of Investigational Vaccine HEPLISAV
Sep 16, 2011: Dynavax To Report Additional Immunogenicity Data For HEPLISAV Phase III Trial
Aug 16, 2007: Dynavax Issued Landmark Patent Covering Second-Generation TLR9 Agonists
May 16, 2008: Dynavax TOLAMBA Chamber Study Misses Primary Endpoint
Feb 16, 2010: Dynavax Receives Canadian Approval To Conduct Phase III Trials Of HEPLISAV Against Hepatitis B
Jun 14, 2005: Dynavax Announces Positive Primary Endpoint Results From Phase II/III Hepatitis B Vaccine Trial
Apr 14, 2010: Dynavax's Chronic Kidney Disease Study Confirms HEPLISAV's Enhanced Seroprotection Against HBV Infection
Aug 12, 2009: Dynavax Announces European Development Strategy For HEPLISAV Hepatitis B Vaccine
Jul 12, 2007: Dynavax Completes Enrollment Of HEPLISAV Phase III
Oct 11, 2010: Dynavax To Report New HEPLISAV Data In Diabetics At IDSA Annual Meeting
Oct 10, 2011: Dynavax Reports Positive Immunogenicity Data From Analysis Of Hypo-Responsive Populations In HEPLISAV Phase III Trial
Sep 10, 2009: Dynavax Reports FDA Removes Clinical Hold On HEPLISAVTM Phase 3 Hepatitis B Vaccine
Jan 10, 2011: Dynavax Completes Enrollment For Phase III Study Of HEPLISAV In Subjects With Chronic Kidney Disease
Dec 09, 2004: Dynavax Announces Positive Interim Results From Phase 2/3 Hepatitis B Vaccine Trial
Feb 09, 2009: Dynavax Announces Receipt Of Communication From The U.S. FDA On HEPLISAV Hepatitis B Vaccine
Feb 08, 2010: Dynavax Initiates Phase III Trial Of Adult Hepatitis B Vaccine HEPLISAV
Dec 07, 2010: Dynavax Reports Positive Phase Ia Results For Universal Flu Vaccine
Dec 07, 2005: Dynavax To Present Data On Phase 2/3 Clinical Trial Of HEPLISAV Hepatitis B Vaccine At ICAAC 2005
Jul 07, 2010: Dynavax Initiates First Human Trial In Universal Flu Vaccine Program
Oct 06, 2011: Dynavax Reports Diabetic Subset Data From Modified Intent To Treat Analysis Of HEPLISAV Phase III Trial In Healthy Adults Over Age 40
Sep 06, 2006: Dynavax Establishes Collaboration For TLR-9 Agonists For Asthma And COPD With AstraZeneca
May 06, 2010: Dynavax Completes Over 2000 First Immunizations In Phase III Study
Oct 05, 2011: Dynavax and AstraZeneca To Advance TLR-9 Agonist Into Clinic For Asthma
Aug 05, 2008: Dynavax And Merck & Co., Inc. Announce Phase III Trial With Investigational Hepatitis B Vaccine (HEPLISAV) Met Its Primary Endpoint
Dec 04, 2006: Dynavax's HEPLISAV Hepatitis B Vaccine Shows 100% Seroprotection Regardless Of Vaccination Schedule In Phase II Trial
Oct 04, 2010: Dynavax's HEPLISAV Demonstrates Superior Seroprotection In Diabetics Compared To Engerix-B
Sep 04, 2002: Dynavax Initiates Phase II Clinical Trial Of ISS Vacine For Hepatitis B - Study Focuses On Single-Injection Approach
Aug 04, 2009: Dynavax Announces Path For HEPLISAV Hepatitis B Vaccine Development
Oct 03, 2011: Dynavax Reports Modified Intent To Treat Analysis From HEPLISAV Phase III Trial In Healthy Adults Over Age 40
Jun 03, 2009: Dynavax Presents Additional Phase III Data For HEPLISAV Hepatitis B Vaccine At DDW Medical Conference
Sep 02, 2004: Dynavax Announces Completion Of Enrollment Of Phase II/III Hepatitis B Prophylactic Vaccine Trial
Nov 01, 2005: Dynavax Initiates US-Based Phase 1 Clinical Trial Of HEPLISAV Hepatitis B Vaccine In Dialysis Population
Nov 01, 2004: Dynavax's Hepatitis B Vaccine Shows More Rapid Immunogenicity, More Durable Protective Response Than Engerix-B In Phase 2 Clinical Trial
Financial Deals Landscape
Dynavax Technologies Corporation, Deals Summary
Dynavax Technologies Corporation, Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Symphony Dynamo Secures $50 Million In Financing
Partnerships
Dynavax Technologies Expands Co-Development Agreement With GlaxoSmithKline
AstraZeneca Extends Co-Development Agreement With Dynavax Technologies For AZD 1419
Dynavax Technologies Extends Research Collaboration With AstraZeneca
GlaxoSmithKline Enters Into An Agreement With Dynavax Technologies
AstraZeneca Enters Into An Agreement With Dynavax
Dynavax Technologies Enters Into Co-Development Agreement With Riken
Licensing Agreements
Merck Enters Into Licensing Agreement With Dynavax Technologies
Dynavax Technologies Enters Into License Agreement With Coley Pharmaceutical
UCB Enters Into Licensing Agreement With Dynavax Technologies
Equity Offering
Dynavax Technologies Completes Public Offering Of $45 Million
Dynavax Technologies Completes First Tranche Of Private Placement Of $2 Million
Dynavax Technologies Completes Private Placement Of $0.18 Million
Dynavax Technologies Completes Public Offering Of $44 Million
Dynavax Technologies Completes Public Offering Of $2.3 Million
Dynavax Completes Private Placement Of $15 Million
Dynavax Completes Public Offering Of $31 Million
Dynavax Completes Public Offering Of $36 Million
Dynavax Completes Initial Public Offering Of $52 Million
Acquisition
Dynavax Technologies Acquires Symphony Dynamo From Symphony Capital Partners
Dynavax Acquires Rhein Biotech From Crucell
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Dynavax Technologies Corporation – Pipeline by Therapy Area and Indication, H2 2011
Dynavax Technologies Corporation – Pipeline by Stage of Development, H2 2011
Dynavax Technologies Corporation – Monotherapy Products in Pipeline, H2 2011
Dynavax Technologies Corporation – Combination Treatment Modalities in Pipeline, H2 2011
Dynavax Technologies Corporation - Phase I, H2 2011
Dynavax Technologies Corporation - Pipeline By Therapeutic Class, H2 2011
Dynavax Technologies Corporation - Pipeline By Target, H2 2011
Dynavax Technologies Corporation – Pipeline By Route of Administration, H2 2011
Dynavax Technologies Corporation – Pipeline By Molecule Type, H2 2011
Dynavax Technologies Corporation – Recent Pipeline Updates, H2 2011
Dynavax Technologies Corporation, Subsidiaries
Dynavax Technologies Corporation, Deals Summary
Symphony Dynamo Secures $50 Million In Financing
Dynavax Technologies Expands Co-Development Agreement With GlaxoSmithKline
AstraZeneca Extends Co-Development Agreement With Dynavax Technologies For AZD 1419
Dynavax Technologies Extends Research Collaboration With AstraZeneca
GlaxoSmithKline Enters Into An Agreement With Dynavax Technologies
AstraZeneca Enters Into An Agreement With Dynavax
Dynavax Technologies Enters Into Co-Development Agreement With Riken
Merck Enters Into Licensing Agreement With Dynavax Technologies
Dynavax Technologies Enters Into License Agreement With Coley Pharmaceutical
UCB Enters Into Licensing Agreement With Dynavax Technologies
Dynavax Technologies Completes Public Offering Of $45 Million
Dynavax Technologies Completes First Tranche Of Private Placement Of $2 Million
Dynavax Technologies Completes Private Placement Of $0.18 Million
Dynavax Technologies Completes Public Offering Of $44 Million
Dynavax Technologies Completes Public Offering Of $2.3 Million
Dynavax Completes Private Placement Of $15 Million
Dynavax Completes Public Offering Of $31 Million
Dynavax Completes Public Offering Of $36 Million
Dynavax Completes Initial Public Offering Of $52 Million
Dynavax Technologies Acquires Symphony Dynamo From Symphony Capital Partners
Dynavax Acquires Rhein Biotech From Crucell

List of Figures
Dynavax Technologies Corporation – Pipeline by Therapy Area and Indication, H2 2011
Dynavax Technologies Corporation – Pipeline by Stage of Development, H2 2011
Dynavax Technologies Corporation – Monotherapy Products in Pipeline, H2 2011
Dynavax Technologies Corporation – Combination Treatment Modalities in Pipeline, H2 2011
Dynavax Technologies Corporation – Pipeline By Therapeutic Class, H2 2011
Dynavax Technologies Corporation - Pipeline By Target, H2 2011
Dynavax Technologies Corporation – Pipeline By Route of Administration, H2 2011
Dynavax Technologies Corporation – Pipeline By Molecule Type, H2 2011

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos